One of the big winners in the health-care space on Friday was Illumina (NASDAQ:ILMN), up 10% for the day after the company outlined its strategic vision. The big news from the report was its new genome sequencer machine, designed to process a staggering 20,000 genomes a year, at a price point of $1,000. This price has long been a target for the industry, and Illumina's reaching it should lead to widespread use of its machine. Releasing its sequencer now also gets it out ahead of competitor Life Technologies' (UNKNOWN:LIFE.DL) $1,000 sequencer, and it positions Illumina to dominate what could be a $20 billion market. In this video, Fool health-care analyst David Williamson tells investors just how big the potential for Illumina in this space could be, and what to watch for from here.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.